Cancer Research

Phase I study of TNFerade for soft tissue sarcoma published

Published in Cancer Weekly, October 5th, 2004

GenVec, Inc., (NASDAQ:GNVC) announced that results from a phase 1 study for its lead product candidate, TNFerade, in patients with soft tissue sarcoma of the extremities were published in the Clinical Cancer Research.

Important results from the dose-escalating study were as follows:

-TNFerade, administered in combination with radiation therapy, was well tolerated with no dose limiting toxicities;

-2 of the 13 patients received TNFerade for palliation (to lessen the severity of symptoms) and did not undergo surgery while 11 patients received TNFerade as preoperative therapy;

-11 of the 13 evaluable...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-10-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry